A Double-Blinded, Randomized, Dose-Comparison Pilot Study to Comparatively Evaluate Efficacy and Safety of Two Doses of Botulinum Toxin Type A Injection for Deltoid Muscle Hypertrophy
- Author:
Young Gue KOH
1
;
Sun Hye SHIN
;
Ka Ram KIM
;
Seung Hoon YEOUM
;
Won-Woo CHOI
;
Kui Young PARK
Author Information
- Publication Type:Original Article
- From:Annals of Dermatology 2023;35(5):355-359
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Botulinum toxin type A (BTX-A) injection is being widely used off-label for muscular hypertrophy, including deltoid muscle hypertrophy. However, very few studies have evaluated the optimal dosage and its clinical response.
Objective:This study aimed to assess the efficacy and safety of different doses of Prabotulinum toxin A (PBoNT) for treating deltoid muscle hypertrophy.
Methods:Twelve particiapants with bilateral deltoid muscle hypertrophy were enrolled and randomly received either 16 U or 32 U of PBoNT. In each participant, the same dose was administered to both deltoid muscles. Both participants and evaluators were blinded. Deltoid muscle thickness and upper arm circumference were measured on day 0, and weeks 2, 4, and 12 after the PBoNT injection.
Results:Upper arm circumference significantly decreased in both groups; however, deltoid muscle thickness was reduced in the 16 U group only. No major complications were reported in both groups. However, a few minor complications were reported in the 16 U injection group.
Conclusion:Both 16 U and 32 U of PBoNT intramuscular injections are safe and effective in treating deltoid hypertrophy.
